Melanoma in 2011: a new paradigm tumor for drug development.
Melanoma has emerged as the paradigm tumor for drug development through mutation-targeted therapies (inhibitors targeting BRAF, MEK, and c-KIT) and immunotherapy. Exploring the combinations of both approaches is a challenge that will require scientific rationale and the cooperation of the pharmaceutical industry. But, with these challenges comes another opportunity to change the paradigms in drug development.
Institut de Cancérologie Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, Paris-Sud, France. alexander.eggermont@igr.fr
Alexander M M
AM
Eggermont
Caroline
C
Robert
D002986:Clinical Trials as Topic; D015195:Drug Design; D049674:History, 21st Century; D006801:Humans; D008545:Melanoma / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009154:Mutation / Q000235:genetics*; D009363:Neoplasm Proteins / Q000235:genetics*
D009363:Neoplasm Proteins